Pfenex
Pfenex Inc. is a biotechnology company based in San Diego, California, specializing in the development of protein therapies to address unmet medical needs. The company is known for its lead product candidate, PF708, which is a therapeutic equivalent to Forteo for treating osteoporosis. Other notable candidates include PF743, a recombinant crisantaspase, and PF745, an extended half-life version of the same protein. Pfenex is also advancing PF810, a next-generation therapeutic in preclinical development, along with additional products such as sparX-1 and sparX-2. The company's innovative Pfēnex Expression Technology, which employs the microorganism Pseudomonas fluorescens, facilitates the rapid and efficient production of therapeutic proteins, vaccines, and biosimilars. Pfenex also holds license and supply agreements for CRM197, a non-toxic variant of diphtheria toxin. As of late September 2020, Pfenex operates as a subsidiary of Ligand Pharmaceuticals Incorporated.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.